Global Pompe Disease Market Size, Share, Growth and Demand Forecast to 2020

The pompe disease market is growing at a significant rate mainly due to special provisions for orphan drugs. Regulatory assistance in emerging nations is one of the major trends seen in the pompe disease market.

Pompe disease is a type of lysergic acid diethylamide (LSD). LSD refers to a group of diseases arising from the increase of specific substrates and is inherited autosomal recessive disorders. Lysergic acid diethylamide is progressive and having uneven age of onset and clinical symptoms. Pompe disease is a hereditary and repeatedly incurable disorder caused by lack of acid alpha glucosidase, an enzyme desired to split down glycogen in particular structures of our body. Patients having pompe disease have little amount of or no acid alpha glucosidase enzyme activity, so break down of glycogen is not possible. The additional glycogen builds up in the patient and is stored in skeletal muscle, heart and other tissues, which causes the progressive indications of pompe disease. Increase of glycogen in certain organs and tissues restraints normal functions of patient’s organs. Pompe disease is also known by other names such as glycogen storage disease type II, acid maltase deficiency, lysosomal alpha-glucosidase deficiency, acid alpha-glucosidase deficiency and glycogenosis type II.

To know more visit: www.psmarketresearch.com/market-analysis/pompe-disease-market

Pompe disease is categorized into two broad categories as adult-onset pompe disease and infantile onset pompe disease. Both the parents pass on one strangely altered copy of the gene to their child. A parent with an altered copy of the gene is known as a carrier and the disease can affect both men and women irrespective of the gender. The disease is acquired by the individuals at the time of birth only, but the onset of indications differs significantly. The researchers have identified more than 300 genetic mutations that can cause pompe disease. Enzyme replacement therapy and diet therapy are useful in dropping the clinical demonstrations of the disease.

Request for Table of Content: www.psmarketresearch.com/market-analysis/Pompe-Disease-Market/toc-sample

Pompe disease is an unusual condition and has an occurrence rate of approximately 1 patient in 38,000 and 1 child in 2,50,000 live births globally. If an infant catch the disease, which is caused by a deficiency of acid alpha-glucosidase enzyme, the survival rate of the infant is expected to be 26%.

Browse Related Report at: www.psmarketresearch.com/industry-report/healthcare

Some of the competitors in the market are Genzyme Corporation, EpiVax, Inc., Amicus Therapeutics, Audentes Therapeutics, BioMarin Pharmaceutical Inc., Valerion Therapeutics, LLC, Oxyrane, and Sangamo BioSciences Inc.

About P&S Market Research

P&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries.

With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication. Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.

Contact:
Abhishek
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: www.psmarketresearch.com

347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)

This release was published on openPR.